**Question:** Initial treatment for pulmonary embolism is:

A. Low molecular weight heparin
B. Fibrinolytic therapy
C. Thrombolytic therapy
D. Anticoagulation therapy

**Correct Answer:** A. Low molecular weight heparin

**Core Concept:** Pulmonary embolism (PE) is a life-threatening condition caused by the blockage of a pulmonary artery by a blood clot. Treatment options depend on the severity of the condition and patient factors, including age, comorbidities, and contraindications.

**Why the Correct Answer is Right:**

Low molecular weight heparin (LMWH) is a widely used anticoagulant medication used in the initial treatment of pulmonary embolism due to the following reasons:

1. **LMWH is a more effective and safer alternative to unfractionated heparin (UFH):** LMWH has a more predictable pharmacokinetic profile, lower risk of bleeding, and can be administered subcutaneously, making it easier for patients to self-administer or receive home therapy.
2. **LMWH has a better safety profile compared to direct oral anticoagulants (DOACs):** DOACs are not recommended for patients with severe renal impairment or those receiving renal replacement therapy.
3. **LMWH is effective in preventing recurrent thrombosis:** LMWH has been shown to be effective in reducing the risk of recurrent venous thromboembolism and reducing mortality in patients with pulmonary embolism.

**Why Each Wrong Option is Incorrect:**

**Option B (Fibrinolytic therapy):**
Fibrinolytic therapy involves breaking down blood clots using thrombolytic agents such as streptokinase or alteplase. While fibrinolytic therapy is an effective treatment for acute, massive pulmonary embolism, it is generally restricted due to the following reasons:

1. **Risk of significant bleeding complications:** Thrombolytic therapy increases the risk of severe bleeding, especially in patients with severe renal impairment, cerebral hemorrhage, or any other bleeding disorders.
2. **Reduced efficacy in elderly patients:** The response to fibrinolytic therapy is often less effective in older patients due to age-related changes in the clotting cascade.

**Option C (Thrombolytic therapy):**
Thrombolytic therapy, similar to fibrinolytic therapy, aims to break down blood clots using thrombolytic agents. It is generally restricted due to the following reasons:

1. **Increased risk of bleeding complications:** Thrombolytic therapy increases the risk of severe bleeding, especially in patients with severe renal impairment, cerebral hemorrhage, or other bleeding disorders.
2. **Reduced efficacy in elderly patients:** The response to thrombolytic therapy is often less effective in older patients due to age-related changes in the clotting cascade.

**Option D (Direct Oral Anticoagulants):**
Direct oral anticoagulants (DOACs) are commonly used for the prevention and treatment of venous thromboembolism. However, in the context of pulmonary embolism treatment, DOACs are generally restricted due to